PerkinElmer gets emergency use authorization for COVID-19 serological test

LabPulse.com staff writers
May 4, 2020
2019 05 28 19 27 1157 Approved Stamp 400

PerkinElmer has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a serological test kit to identify COVID-19 antibodies.

Developed by PerkinElmer subsidiary Euroimmun, the SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) test is designed to detect immunoglobulin G (IgG) antibodies. In development, the serological kit demonstrated 99% specificity and 100% sensitivity when used 21 days after symptom onset, according to the firm.

PerkinElmer said that Euroimmun can manufacture millions of assays per month and intends to further build production capacity. The company said that it has been shipping the kits to laboratories across the world since March.

Latest in Emergency Use Authorization
Covid Test Preschool Social
iHealth gets EUA for combination COVID-19/influenza at-home test
May 10, 2024
3d Closeup Coronavirus Social
FDA issues EUAs for 2 POC COVID-19 tests
October 4, 2023
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Fda Button Social
FDA authorizes Discover Labs to run molecular COVID-19 test at its Texas facility
July 7, 2023
Related Stories
Covid Diagnostic Test Kit Social
Emergency Use Authorization
CorDx receives FDA Emergency Use Authorization for COVID-19 antigen test
2020 04 30 22 13 6857 Coronavirus Swab Ppe 400
CE mark
Euroimmun debuts new ELISA SARS-COV-2 antigen test
2020 06 15 18 14 5259 Swab Sample Collection 400
Influenza
Euroimmun launches test to distinguish between COVID, flu
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Emergency Use Authorization
iHealth gets EUA for combination COVID-19/influenza at-home test
By LabPulse.com staff writers
Diagnostics developer iHealth Labs has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its 3-in-1 COVID-19/Flu A&B Rapid Test Kit for over-the-counter home use.
May 10, 2024
Covid Test Preschool Social
FDA issues EUAs for 2 POC COVID-19 tests
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) granted emergency use authorizations (EUAs) for two separate point-of-care (POC) assays for SARS-CoV-2 developed by Tangen Biosciences and SD Biosensor.
October 4, 2023
3d Closeup Coronavirus Social
FDA awards EUA to Alphadera Labs’ COVID-19 test
By Nick Paul Taylor
Alphadera Labs received the EUA after evaluating its test on 60 clinical nasopharyngeal swabs specimens. ALPHADx provided the same results as a “highly sensitive” FDA-authorized molecular SARS-CoV-2 test.
August 2, 2023
Coronavirus Covid Blue Social
FDA authorizes Discover Labs to run molecular COVID-19 test at its Texas facility
By Nick Paul Taylor
Under the terms of the EUA, Discover Labs can run the COVID-19 test at its CLIA-certified Austin facility. The test is for prescription use only.
July 7, 2023
Fda Button Social
Cue Health receives FDA emergency use authorization for molecular mpox test
By Leo O'Connor
The test demonstrated high accuracy in clinical trials, achieving 100% concordance with the Center for Disease Control and Prevention’s (CDC's) mpox test on the samples tested, Cue Health said.
March 20, 2023
Monkeypox Virus Social
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
By LabPulse.com staff writers
The development of the rapid antigen test was funded under an $11.8 million contract through the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative.
February 27, 2023
Covid Test Preschool Social
Lucira Health files for bankruptcy despite receiving FDA green light
By Leo O'Connor
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
Business Deal Corporate Social
FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses
By LabPulse.com staff writers
In people with symptoms, the Lucira COVID-19 & Flu Test correctly identified 99.3% of negative and 90.1% of positive influenza A samples; 100% of negative and 88.3% of positive COVID-19 samples; and 99.9% of negative influenza B samples, the FDA said.
February 24, 2023
Fda Button Social
FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector
By LabPulse.com staff writers
Anavasi said its point-of-care platform will enable the rapid development of tests to detect viral and bacterial targets, including influenza, respiratory syncytial virus (RSV), and sexual health-related strains, among others.
February 13, 2023
Virus Coronavirus Covid 19 Social
FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care
The Xpert Mpox test is a real-time polymerase chain reaction assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.
February 10, 2023
3 D Monkeypox Infecting Cell Social
BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test
By LabPulse.com staff writers
The test uses a single nasal or nasopharyngeal swab sample to identify and distinguish whether a patient has COVID-19, the flu, RSV, or some combination of the three, with results available in two hours.
February 8, 2023
Quality Check Mark Social
LumiraDx obtains FDA authorization for test to detect flu A, flu B, SARS-CoV-2
By LabPulse.com staff writers
The test leverages a single-step direct method for nucleic acid extraction and amplification on validated open RT-PCR instruments.
February 7, 2023
Covid 19 Antibody Social
Page 1 of 14
Next Page